Prognostic Factors of Pulmonary Carcinoid Tumors Abstract #2029

Introduction: Pulmonary carcinoids (PC) are rare malignant neoplasms that account for approximately 1% of all lung cancers. PCs are classified by histological criteria as either typical (TC) or atypical (AC). Histological subtype is the most studied prognostic factor.
Aim(s): The aim of this study was to evaluate if other tissue or clinical features associated with patient outcomes.
Materials and methods: We retrospectively reviewed clinical records of 133 PC patients who were surgically treated at our institution between 1990 and 2013. Tissue specimens were re-evaluated, processed into tissue microarray format and stained immunohistochemically with serotonin, calcitonin, adrenocorticotropic hormone (ACTH), thyroid transcription factor-1 (TTF-1) and Ki-67. Survival analyses with Cox regression and Kaplan-Meier were performed.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: MSc Tiina Vesterinen

To read results and conclusion, please login ...

Further abstracts you may be interested in

#65 Deletions of 11q21-q25 are associated with atypical lung carcinoids and a poor clinical outcome
Introduction: Lung carcinoids comprise a group of smoking-unrelated neuroendocrine tumors, which can be classified in typical (TC) and atypical (AC) carcinoids. Classification is complex and its accuracy to predict disease outcome is variable. In a previous array comparative genomic hybridization (arrayCGH) study, we showed that the average number of chromosomal alterations (≥ 1Mb) was significantly higher in ACs than in TCs (512 v. 226 per tumor) and that the most common region of chromosome loss was 11q21-q25 (Neuroendocrinology 2009;90:136-137).
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: MSc Dorian RA Swarts
#2050 Finding the Ways to Determine the Prognosis of Pulmonary Carcinoids with Certain Genes/Markers in Pakistan
Introduction: Pulmonary neuroendocrine tumors are classified into four subtypes from well differentiated to poorly differentiated high grade large cell neuroendocrine carcinomas. Because of the difficult histological classification and a cancer free period following surgery, it is often difficult to predict certain prognostic factors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#737 Impact of Ki-67 Proliferative Index on Survival in Patients with Typical and Atypical Pulmonary Carcinoids
Introduction: Currently pulmonary carcinoids are separated into typical and atypical tumors based on mitotic count and presence of necrosis, according to the WHO classification. Whereas for GEP NETs the ENETS Guidelines have been incorporated into the WHO classification and grading is based on mitotic counts and Ki-67 index, the use of the Ki-67 index for grading pulmonary carcinoids is still under debate.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Martina Rudelius
#653 Interobserver Variability of Pulmonary Carcinoids
Introduction: Lung carcinoids are neuroendocrine tumors histopathologically classified into typical (TC; no necrosis, <2 mitoses/2 mm2) and atypical (AC; necrosis or 2-10 mitoses/2 mm2). Identification of mitoses may be hampered by the presence of apoptotic cells, and reported prediction of prognosis based on histopathology varies, especially for ACs.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MSc Dorian Swarts
#2174 Clinicopathologic Features and Treatment Outcome of 225 Newly Diagnosed Pulmonary Carcinoids: A Single Center Experience of 28 Years
Introduction: Data on pulmonary carcinoids are scarce.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: M.D. Hong Zhao
Authors: Li Q, Zhou Y, Zhang Y, Chi Y, ...